Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. (APRE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · APRE · as of Jun 8, 2026
Key Statistics
Explore Aprea Therapeutics, Inc. Data
apre stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 50.0%
Competitors & Peers
apre competitorsAPRE
ACXP
ADIL
APVO
BCDA
CELZStock Performance
Full HistoryAbout Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on mo…
what is aprea therapeutics, inc. · apre stock overview · aprea therapeutics, inc. company profile · who is aprea therapeutics, inc. ceo · apre NASDAQ · aprea therapeutics, inc. headquarters · aprea therapeutics, inc. business segments
About Stock Overview & Key Data
Aprea Therapeutics, Inc. (APRE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 3, 2019. As of the latest trading session, APRE stock price is $0.73, with a market capitalization of $4.8M. The stock has returned -60.09% over the past 12 months and -13.92% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Aprea Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Aprea Therapeutics, Inc. reported revenue of — and net income of -$12.6M. For detailed data — including Aprea Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Aprea Therapeutics, Inc. (APRE) stock price is $0.73. The stock is traded on NASDAQ under the ticker symbol APRE. The 52-week range is $0.55 – $2.22.